The International Database on Organ donation and Transplantation – COVID19

SARS-CoV-2 infection has been a challenge for health systems worldwide, causing a dramatic consumption of resources to cope with this pandemic caused by this recently identified virus. Solid information about SARS-CoV-2 (from a pathophysiological, clinical and therapeutic point of view) is scarce. On many occasions, these questions have been answered based on available knowledge from similar viruses such as SARS-CoV and MERS.

Due to the potential severity of this disease and the absence of current tools able to definitively modify its natural history, many are the ongoing research works that have been started since the description of the first case of COVID-19. Currently, our clinical practice in this type of infection is based on data especially from retrospective studies whose scientific power is questionable and which, on many occasions, provide contradictory messages.

These handicaps associated with the management and knowledge of COVID-19 extend, even with a greater lack of knowledge, to the population of recipients of a solid organ transplant (SOT) and to organ donation protocols, which have been adapted (in occasions drastically) to this new scenario. However, again, the data that supports these protocols and the available evidence on the management of organ donation and the recipient of a SOT are, likewise, of little scientific solidity.

As a result of this absence of solid evidence that allows for a significant improvement in the management of this risk population, The International Database on Organ donation and Transplantation – COVID19 (IDOTCOVID) has been designed. The present database tries to exhaustively collect the demographic, clinical, analytical and therapeutic data that of SOT recipients with COVID-19 and, afterwards, to extrapolate large-scale conclusions to provide reliable information and, more importantly, to guide in a solid way the future management of this population.

One of the main objectives of this project is the development of a tool that helps in the management of immunosuppression and the treatment of COVID19 infection in SOT recipients.

To achieve this, the following objectives have been designed to be developed in stages and progressively:

1. Creation of an international database that includes all SOT recipient patients with COVID19 infection (confirmed or suspected);

2. Inclusion of different clinical and analytical data with recognized prognostic factor in the general population;

3. Inclusion of treatment data, including management of immunosuppression and clinical outcomes;

4. Development of a Machine Learning algorithm that can assist the scientific community in updating their treatment management and immunosuppression protocols in this high-risk population;

Ethical IRB Protocol

User Guide